JP7266592B2 - ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用 - Google Patents
ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用 Download PDFInfo
- Publication number
- JP7266592B2 JP7266592B2 JP2020521968A JP2020521968A JP7266592B2 JP 7266592 B2 JP7266592 B2 JP 7266592B2 JP 2020521968 A JP2020521968 A JP 2020521968A JP 2020521968 A JP2020521968 A JP 2020521968A JP 7266592 B2 JP7266592 B2 JP 7266592B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methoxy
- pyrimidin
- yloxy
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573251P | 2017-10-17 | 2017-10-17 | |
| US62/573,251 | 2017-10-17 | ||
| PCT/US2018/056190 WO2019079373A1 (en) | 2017-10-17 | 2018-10-17 | PYRIMIDINE TBK / IKKε INHIBITORY COMPOUNDS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537671A JP2020537671A (ja) | 2020-12-24 |
| JP2020537671A5 JP2020537671A5 (enExample) | 2021-11-25 |
| JP7266592B2 true JP7266592B2 (ja) | 2023-04-28 |
Family
ID=64110185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521968A Active JP7266592B2 (ja) | 2017-10-17 | 2018-10-17 | ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230019491A1 (enExample) |
| EP (1) | EP3697772A1 (enExample) |
| JP (1) | JP7266592B2 (enExample) |
| KR (1) | KR20200072519A (enExample) |
| CN (1) | CN111247135A (enExample) |
| AU (1) | AU2018352699A1 (enExample) |
| BR (1) | BR112020007466A2 (enExample) |
| CA (1) | CA3078579A1 (enExample) |
| IL (1) | IL273891A (enExample) |
| MX (1) | MX2020003507A (enExample) |
| RU (1) | RU2020115596A (enExample) |
| SG (1) | SG11202003407VA (enExample) |
| TW (1) | TWI802604B (enExample) |
| WO (1) | WO2019079373A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11440899B2 (en) * | 2017-10-17 | 2022-09-13 | Merck Patent Gmbh | Pyrimidine TBK/IKKe inhibitor compounds and uses thereof |
| KR102695210B1 (ko) | 2018-06-05 | 2024-08-13 | 크리네틱스 파마슈티칼스, 인크. | 멜라노코르틴 아형-2 수용체(mc2r) 길항제 및 이의 용도 |
| CN112552280A (zh) * | 2019-09-25 | 2021-03-26 | 常州强力先端电子材料有限公司 | 一种高产酸的磺酰亚胺类光产酸剂 |
| WO2021091788A1 (en) * | 2019-11-07 | 2021-05-14 | Crinetics Pharmaceuticals, Inc. | Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof |
| JP7672406B2 (ja) | 2019-12-18 | 2025-05-07 | クリネティックス ファーマシューティカルズ，インク． | Ｇｅｍ－二置換ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| JP7651574B2 (ja) | 2019-12-23 | 2025-03-26 | クリネティックス ファーマシューティカルズ，インク． | スピロ環式ピペリジンメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| BR112023018816A2 (pt) | 2021-03-19 | 2023-10-31 | Crinetics Pharmaceuticals Inc | Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença |
| CN117447407B (zh) * | 2023-12-19 | 2024-06-11 | 潍坊医学院 | 一种JAK2抑制剂Pacritinib及其中间体的制备方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010514822A (ja) | 2007-01-05 | 2010-05-06 | サノフイ−アベンテイス | 新規なフェニル（４−フェニルピリミジン−２−イル）アミン誘導体、薬物としてのこれらの調製、医薬組成物および基本的にｉｋｋ阻害剤としてのこれらの使用 |
| JP2010538076A (ja) | 2007-09-04 | 2010-12-09 | ザ スクリプス リサーチ インスティチュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| JP2013507449A (ja) | 2009-10-12 | 2013-03-04 | ミレクシス， インコーポレイテッド | ＴＢＫ１および／またはＩＫＫεの阻害剤としてのアミノ−ピリミジン化合物 |
| JP2013531055A (ja) | 2010-07-19 | 2013-08-01 | ドメイネクス リミテッド | プロテインキナーゼＩＫＫε及び／又はＴＢＫ−１の阻害剤としてのピリミジン化合物、それらの製造方法及びそれらを含む医薬組成物 |
| JP2014510794A (ja) | 2011-04-12 | 2014-05-01 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | ＩＫＫ関連キナーゼεおよびＴＡＮＫ結合キナーゼ１の阻害剤の組成物および治療的使用 |
| JP2014526447A (ja) | 2011-09-09 | 2014-10-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼインヒビターとしてのベンゾニトリル誘導体 |
| WO2017003995A1 (en) | 2015-06-29 | 2017-01-05 | Merck Patent Gmbh | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF |
-
2018
- 2018-10-17 SG SG11202003407VA patent/SG11202003407VA/en unknown
- 2018-10-17 BR BR112020007466-7A patent/BR112020007466A2/pt not_active IP Right Cessation
- 2018-10-17 KR KR1020207014078A patent/KR20200072519A/ko not_active Withdrawn
- 2018-10-17 TW TW107136567A patent/TWI802604B/zh not_active IP Right Cessation
- 2018-10-17 WO PCT/US2018/056190 patent/WO2019079373A1/en not_active Ceased
- 2018-10-17 CN CN201880067979.0A patent/CN111247135A/zh active Pending
- 2018-10-17 MX MX2020003507A patent/MX2020003507A/es unknown
- 2018-10-17 AU AU2018352699A patent/AU2018352699A1/en not_active Abandoned
- 2018-10-17 JP JP2020521968A patent/JP7266592B2/ja active Active
- 2018-10-17 US US16/756,769 patent/US20230019491A1/en not_active Abandoned
- 2018-10-17 CA CA3078579A patent/CA3078579A1/en active Pending
- 2018-10-17 EP EP18797386.2A patent/EP3697772A1/en not_active Withdrawn
- 2018-10-17 RU RU2020115596A patent/RU2020115596A/ru unknown
-
2020
- 2020-04-07 IL IL273891A patent/IL273891A/en unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010514822A (ja) | 2007-01-05 | 2010-05-06 | サノフイ−アベンテイス | 新規なフェニル（４−フェニルピリミジン−２−イル）アミン誘導体、薬物としてのこれらの調製、医薬組成物および基本的にｉｋｋ阻害剤としてのこれらの使用 |
| JP2010538076A (ja) | 2007-09-04 | 2010-12-09 | ザ スクリプス リサーチ インスティチュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| JP2013507449A (ja) | 2009-10-12 | 2013-03-04 | ミレクシス， インコーポレイテッド | ＴＢＫ１および／またはＩＫＫεの阻害剤としてのアミノ−ピリミジン化合物 |
| JP2013531055A (ja) | 2010-07-19 | 2013-08-01 | ドメイネクス リミテッド | プロテインキナーゼＩＫＫε及び／又はＴＢＫ−１の阻害剤としてのピリミジン化合物、それらの製造方法及びそれらを含む医薬組成物 |
| JP2014510794A (ja) | 2011-04-12 | 2014-05-01 | アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド | ＩＫＫ関連キナーゼεおよびＴＡＮＫ結合キナーゼ１の阻害剤の組成物および治療的使用 |
| JP2014526447A (ja) | 2011-09-09 | 2014-10-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼインヒビターとしてのベンゾニトリル誘導体 |
| WO2017003995A1 (en) | 2015-06-29 | 2017-01-05 | Merck Patent Gmbh | TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020003507A (es) | 2020-07-22 |
| EP3697772A1 (en) | 2020-08-26 |
| RU2020115596A3 (enExample) | 2021-11-18 |
| SG11202003407VA (en) | 2020-05-28 |
| RU2020115596A (ru) | 2021-11-18 |
| IL273891A (en) | 2020-05-31 |
| JP2020537671A (ja) | 2020-12-24 |
| AU2018352699A1 (en) | 2020-05-28 |
| TWI802604B (zh) | 2023-05-21 |
| CN111247135A (zh) | 2020-06-05 |
| US20230019491A1 (en) | 2023-01-19 |
| TW201922735A (zh) | 2019-06-16 |
| KR20200072519A (ko) | 2020-06-22 |
| CA3078579A1 (en) | 2019-04-25 |
| WO2019079373A1 (en) | 2019-04-25 |
| BR112020007466A2 (pt) | 2020-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI802604B (zh) | 嘧啶ＴＢＫ/ＩＫＫε抑制劑化合物及其用途 | |
| AU2015349899B2 (en) | Heteroaryl compounds as IRAK inhibitors and uses thereof | |
| US10428080B2 (en) | TBK/IKK inhibitor compounds and uses thereof | |
| JP7651590B2 (ja) | アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用 | |
| JP7284161B2 (ja) | ピリミジンＴＢＫ／ＩＫＫεインヒビター化合物およびそれらの使用 | |
| HK40086197A (en) | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators | |
| HK1242303A1 (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| HK1242303B (en) | Heteroaryl compounds as irak inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211015 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211015 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220922 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221020 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230316 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230404 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230418 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7266592 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |